D. Ando

发表

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

J. Orange, C. June, Jeffrey C. Miller, 2008, Nature Biotechnology.

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Wei-Ting Hwang, Ian Frank, Gabriela Plesa, 2014, The New England journal of medicine.

Treatment of traumatic brain injury using zinc-finger protein gene therapy targeting VEGF-A.

M. Fehlings, M. Giedlin, E. Park, 2012, Journal of neurotrauma.

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

E. Small, G. Wilding, M. Carducci, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

CERE-120 Prevents Irradiation-Induced Hypofunction and Restores Immune Homeostasis in Porcine Salivary Glands

M. Moore, C. Zheng, P. Edwards, 2020, Molecular therapy. Methods & clinical development.

The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider

R. Vile, D. Kirn, D. Ando, 2002, Cancer Gene Therapy.

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

F. Marshall, A. Partin, S. Piantadosi, 1999, Cancer research.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies

F. Marshall, A. Partin, S. Piantadosi, 2000, Cancer Chemotherapy and Pharmacology.

Comparison of Serum Interleukin-10 (IL-10) Levels Between Normal Volunteers and Patients with Advanced Melanoma

J. Nemunaitis, D. Ando, D. Martineau, 2001, Cancer investigation.

Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma

J. Nemunaitis, M. Pike, D. Ando, 1999, Cancer Gene Therapy.

Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model.

E. Sercarz, B. Hahn, D. Ando, 1987, Journal of immunology.

Two minor determinants of myelin basic protein induce experimental allergic encephalomyelitis in SJL/J mice

L. Hood, D. Kono, D. Ando, 1988, The Journal of experimental medicine.

Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat.

R. Zimmerman, D. Ando, S. L. Aukerman, 1994, The Journal of infectious diseases.

Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice.

J. Merrill, D. Kono, D. Hinton, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein

L. Hood, E. Sercarz, D. Kono, 1989, The Journal of experimental medicine.

ZFN-Mediated Gene Targeting at the Albumin Locus in Liver Results in Therapeutic Levels of Human FIX in Mice and Non-Human Primates

Yolanda Santiago, David E. Paschon, E. Rebar, 2015 .

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery

Luigi Naldini, Fyodor D Urnov, Angelo Lombardo, 2007, Nature Biotechnology.

Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus.

K. Kalunian, H. Middlekauff, B. Hahn, 1988, The American journal of medicine.

Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer

J. Nemunaitis, E. Small, J. Simons, 2007, Clinical Cancer Research.

Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer

S. Piantadosi, J. Simons, M. Carducci, 2006, Clinical Cancer Research.

Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy

L. Hood, E. Sercarz, Vipin Kumar, 1988, Cell.

Selectively replicating oncolytic adenoviruses as cancer therapeutics.

P. Working, D. Ando, De-chao Yu, 2002, Current opinion in molecular therapeutics.

PHARMACOLOGIC, TOXICOLOGIC, AND MARROW TRANSPLANTATION STUDIES IN DOGS GIVEN SUCCINYL ACETONE

H. Deeg, M. Pepe, J. Young, 1992, Transplantation.

Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials.

A. Levine, C. June, H. Kiem, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication.

D. Porter, B. Levine, C. June, 2021, The Journal of clinical investigation.

Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Gabriela Plesa, Bruce L Levine, James L Riley, 2013, Human gene therapy.

Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-NaI« ve Prostate Cancer

S. Piantadosi, J. Simons, M. Carducci, 2006 .

Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.

M. Noguchi, H. Akaza, R. Mulligan, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Advanced renal cell carcinoma treated with granulocyte‐macrophage colony‐stimulating factor gene therapy: A clinical course of the first Japanese experience

M. Noguchi, H. Akaza, R. Mulligan, 2002, International journal of urology : official journal of the Japanese Urological Association.

Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury

M. Fehlings, M. Giedlin, S. Spratt, 2014, PloS one.

An engineered transcription factor which activates VEGF-A enhances recovery after spinal cord injury

M. Fehlings, S. Spratt, Gary K. Lee, 2010, Neurobiology of Disease.

Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype.

E. Sercarz, D. Kono, D. Ando, 1989, Cellular immunology.

Gene Editing: Regulatory and Translation to Clinic.

D. Ando, Kathleen E. Meyer, Kathleen Meyer, 2017, Hematology/oncology clinics of North America.

Detection of native and denatured DNA antibody forming cells by the enzyme-linked immunospot assay. A clinical study of (New Zealand black x New Zealand white)F1 mice.

B. Hahn, D. Ando, F. Ebling, 1986, Arthritis and rheumatism.

Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients

J. Nemunaitis, D. Hoon, S. Huang, 2000, Cancer Gene Therapy.

Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice.

J. Merrill, D. Kono, D. Hinton, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery

P. Gregory, F. Urnov, L. Naldini, 2007, Nature Biotechnology.

Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.

S. Rosenberg, R. Morgan, David E. Paschon, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma.

J. Nemunaitis, J. Pippen, W. Meyer, 1999, Human gene therapy.

Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.

J. Nemunaitis, W. Meyer, D. Martineau, 1998, Cancer gene therapy.

Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor.

J. Nemunaitis, F. Appelbaum, J. Singer, 1993, Blood.

Long-Term Follow-up of Patients With Invasive Fungal Disease Who Received Adjunctive Therapy With Recombinant Human Macrophage Colony-Stimulating Factor

J. Nemunaitis, J. Singer, R., 2003 .

Idiotypic spreading promotes the production of pathogenic autoantibodies.

K. Kalunian, B. Hahn, D. Ando, 1988, Journal of autoimmunity.

974. Towards Gene Knock out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs)

C. June, Jeffrey C. Miller, E. Rebar, 2005 .

A prescription for gene therapy: The first cabo gene therapy working group

E. B. Butler, S. Scherer, J. Nemunaitis, 2000 .

758. Towards Gene Knock out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs)

C. June, Jeffrey C. Miller, E. Rebar, 2006 .

Gene therapy for traumatic central nervous system injury and stroke using an engineered zinc finger protein that upregulates VEGF-A.

M. Fehlings, S. Spratt, Gary K. Lee, 2011, Journal of neurotrauma.

Gene therapy and molecular immunology unite to give new life to cancer immunotherapy.

D. Ando, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.

J. Nemunaitis, M. Pike, D. Ando, 1999, Cancer gene therapy.

A phase I study of vaccination with lethally irradiated, autologous nonsmall cell lung carcinoma cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor

M. Mihm, G. Dranoff, D. Sugarbaker, 2000 .